Summary: In this phase 1, double-blind, placebo-controlled trial, 32 healthy Chinese adults received once-daily oral semaglutide (3 mg escalating to 14 mg) or placebo for 12 weeks. Steady-state exposure rose dose-dependently (AUC 233, 552 and 1288 h·nmol/L for 3, 7 and 14 mg), with significant reductions in body weight and fasting plasma glucose versus placebo and a tolerability profile typical of GLP-1 receptor agonists.
PICO Summary
| Element | Detail |
|---|---|
| Population | 32 healthy Chinese adults; single-centre, multiple-dose phase 1 trial in China (NCT04016974) |
| Intervention | Once-daily oral semaglutide, escalating 3 mg to 7 mg to 14 mg over 12 weeks (active arm within n=32) |
| Comparison | Matching oral placebo, once daily for 12 weeks (placebo arm within n=32) |
| Outcome | Primary (PK): steady-state AUC(0-24h) 233, 552 and 1288 h·nmol/L for 3, 7 and 14 mg, dose-dependent and close to dose-proportional. Secondary (PD): significant reduction in body weight (p=0.0001) and fasting plasma glucose (p=0.0011) versus placebo at end of treatment. Safety: no severe or blood-glucose-confirmed symptomatic hypoglycaemia, no serious adverse events and no deaths; most frequent adverse events were gastrointestinal. No 95% confidence intervals, absolute risk reduction or number needed to treat are applicable to this pharmacology endpoint set. |
Expert Commentary
This is a pharmacokinetic bridging study, and it should be read as such rather than as an efficacy trial. The primary purpose was to characterise oral semaglutide exposure in a healthy Chinese population, and on that narrow question the result is clean: steady-state AUC increased dose-dependently and remained close to dose-proportional across 3, 7 and 14 mg, consistent with data generated in other populations. The reductions in body weight and fasting plasma glucose are reported as statistically significant versus placebo, but they are supportive secondary pharmacodynamic signals in healthy volunteers over twelve weeks, not evidence of clinical benefit in people living with type 2 diabetes. The single largest limitation is therefore one of indirectness: a sample of 32 healthy adults at a single centre cannot speak to glycaemic control, cardiovascular outcomes or durable weight effects in the patients who would actually be prescribed this drug. The trial was funded by the manufacturer and several authors are employees, which warrants the usual caution even though the pharmacology endpoints are objective. Can I use this with my patients? Not yet as a basis for treatment decisions; its value is regulatory and pharmacological, supporting that the established oral semaglutide dosing behaves predictably in Chinese adults. Confirmatory efficacy and safety data in the target patient population should anchor any prescribing.
References
Xie P, Abildlund MT, Bækdal TA, He X, Lyauk YK, Patted URH, Ning Z, Shi A. A phase 1, randomized, double-blind, placebo-controlled trial investigating the pharmacokinetics, pharmacodynamics, safety and tolerability of oral semaglutide in healthy Chinese subjects. Diabetes Obes Metab. 2024;26(8):3068-3077. doi:10.1111/dom.15624